Clinical trials4 Jun 2026 10:48
After doing some research on POLB 001 and what results have shown so far, all i can say is i'm excited, long term, to be in this share.
It's hard to see where the risk is in regards to the actual drug, any negative results would certainly go against what I have been reading.
The drug seems like a win/win for everyone, with potentially most immunotherapies treatments starting with POLB 001.
In regards to the compamy being sold out, that's not for me to guess at, but I doubt anyone invested here will lose out in the next 6 month. Someone mentioned 10 bag, and for the first time I can actually see that here.